Taro Pharmaceutical Industries (TARO) Earning Somewhat Positive News Coverage, Analysis Finds
News headlines about Taro Pharmaceutical Industries (NYSE:TARO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.829149408495 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Stock Rating Lowered by BidaskClub (americanbankingnews.com)
- Taro Pharmaceutical Industries Ltd. (TARO) Downgraded by TheStreet to C+ (americanbankingnews.com)
- Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : August 9, 2017 (finance.yahoo.com)
- IHS Markit Score upgrades Taro Pharmaceutical Industries Ltd to 71 out of 100, despite ranking positively in only one IHS Markit category. (finance.yahoo.com)
- Taro Provides Results for Quarter Ended June 2017 (finance.yahoo.com)
Taro Pharmaceutical Industries (NYSE:TARO) opened at 98.16 on Friday. The company has a market capitalization of $3.97 billion, a PE ratio of 10.00 and a beta of 0.64. The stock has a 50 day moving average of $113.41 and a 200-day moving average of $112.78. Taro Pharmaceutical Industries has a 12-month low of $92.28 and a 12-month high of $137.38.
Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings results on Monday, May 22nd. The company reported $2.05 EPS for the quarter. Taro Pharmaceutical Industries had a return on equity of 20.08% and a net margin of 49.69%. The business had revenue of $196.41 million for the quarter. Equities analysts expect that Taro Pharmaceutical Industries will post $9.49 earnings per share for the current year.
TARO has been the topic of several recent analyst reports. BidaskClub raised shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Credit Suisse Group cut shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a report on Tuesday, May 23rd. Finally, TheStreet cut shares of Taro Pharmaceutical Industries from a “b-” rating to a “c” rating in a report on Thursday, June 15th.
ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/taro-pharmaceutical-industries-taro-earning-somewhat-positive-news-coverage-analysis-finds.html.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.
Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.